Strong growth from Vyepti and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026

On August 12, 2026, ODDITY Tech Ltd (ODD) shares rose 3.4% to a current price of $12.90. This price sits within a 52-week range of $9.25 to $64.23, highlighting

Empowered Funds LLC acquired a new position in ODDITY Tech Ltd. (NASDAQ: ODD) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 95,323 shares of the company's stock, valued at approximately $1,275,000. Empowered Funds LLC owned approximately 0.17%

Amundi raised its stake in shares of ODDITY Tech Ltd. (NASDAQ: ODD) by 17.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 434,945 shares of the company's stock after purchasing an additional 65,647 shares during the quarter. Amundi

Fosun International Wins Three Awards from Global Banking and Finance Review, Gaining International Recognition for its ESG Performance, Corporate

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it will release its second quarter 2026 financial results before the market open on Wednesday, September 9, 2026, to be followed by a conference call at 8:30 a.m.

Fosun International Garners Five Awards from Corporate Governance Asia PR Newswire HONG KONG, July 2, 2026

REX Shares ("REX") and Tuttle Capital Management ("TCM") today announce that listed options are now available on the T-REX 2X Long SpaceX Daily Target ETF (NYS

Oddity Tech is downgraded from buy to hold due to unresolved customer acquisition cost headwinds and weak first-order growth. Q1 2026 revenue declined 26% y/y, with first orders down ~50% and margins deteriorating; Q2 guidance suggests continued revenue contraction. The investment thesis now hinges on whether CPA normalization is temporary or structural, as elevated CPA undermines the core acquisition engine.